Zealand Pharma A/S (OTCMKTS:ZLDPF) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) in a research note released on Friday morning, MarketBeat.com reports. The firm issued an overweight rating on the stock.

Zealand Pharma A/S Trading Up 3.5 %

ZLDPF opened at $126.00 on Friday. The company has a current ratio of 35.57, a quick ratio of 35.57 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average price is $122.70 and its 200 day moving average price is $116.15. Zealand Pharma A/S has a fifty-two week low of $41.66 and a fifty-two week high of $141.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.06). Zealand Pharma A/S had a negative return on equity of 22.95% and a negative net margin of 1,375.16%. The company had revenue of $4.93 million for the quarter, compared to analyst estimates of $0.50 million. Equities research analysts predict that Zealand Pharma A/S will post -2.48 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.